FINAL TERMS

22 February 2022

Intesa Sanpaolo S.P.A.

Legal entity identifier (LEI): 2W8N8UU78PMDQKZENC08

MAX LONG CAP CERTIFICATES on EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) Index due 31.03.2032

commercial name: ***Intesa Sanpaolo S.p.A. Certificate Equity Protection Performance con Leva 3 su Indice EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) - PROTEZIONE 100% - Scadenza 31.03.2032***

under the Warrants and Certificates Programme IMI Corporate & Investment Banking

PART A – CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Terms and Conditions set forth in the Base Prospectus dated 27 May 2021 and the supplements to the Base Prospectus dated 9 August 2021, 2 November 2021 and 15 February 2022, which together constitute a base prospectus for the purposes of the Prospectus Regulation as amended. This document constitutes the Final Terms of the Securities described herein for the purposes of Article 8(1) of the Prospectus Regulation and must be read in conjunction with the Base Prospectus, as supplemented. Full information on the Issuer and the offer of the Securities is only available on the basis of the combination of these Final Terms and the Base Prospectus, as supplemented. The Base Prospectus and the supplements to the Base Prospectus are available for viewing during normal business hours at the registered office of the Issuer and the specified offices of the Principal Security Agent. The Base Prospectus and the supplements to the Base Prospectus have been published on the websites of the Luxembourg Stock Exchange (www.bourse.lu) and the Issuer (www.intesasanpaolo.prodottiequotazioni.com). An issue specific summary of the Securities is annexed to these Final Terms. In the case of the Securities admitted to trading on the regulated market of the Luxembourg Stock Exchange, the Final Terms will be published on the website of the Luxembourg Stock Exchange and of the Issuer.

References herein to numbered Conditions are to the terms and conditions of the relevant series of Securities and words and expressions defined in such terms and conditions shall bear the same meaning in these Final Terms insofar as they relate to such series of Securities, save as where otherwise expressly provided.

These Final Terms relate to the series of Securities as set out in "Specific Provisions for each Series" below. References herein to "Securities" shall be deemed to be references to the relevant Certificates that are the subject of these Final Terms and references to "Securities" and "Security" shall be construed accordingly.

1. Specific provisions for each Series:

	Series Number	**No. of Securities issued**	**Issue Price per Security**
	770	Up to 150,000	EUR 1,000

2. Tranche Number: Not applicable

3. Minimum Exercise Amount: 1 (one) Certificate

4. Minimum Trading Amount: 1 (one) Certificate

5. Consolidation: Not applicable

6.	Type of Securities and Underlying(s):	(a)	The Securities are Certificates. The Certificates are Index Securities.
		(b)	The item to which the Securities relate is the EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) index (ISIN Code: CH1123123734; Bloomberg Code: ISX5HCTD <Index>) (the "**Underlying**" or the "**Index**").
		Information about the Index may be found on the website of the Index Sponsor www.stoxx.com	
		The EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) Index is provided by STOXX Limited. As at the date of these Final Terms, STOXX Limited appears in the register of administrators and benchmarks established and maintained by ESMA pursuant to Article 36 of the Benchmark Regulation.	
		DISCLAIMER - ***EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) Index***	
		*The EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) index is the intellectual property (including registered trademarks) of STOXX Limited, Zug, Switzerland ("**STOXX**"), Deutsche Börse Group or their licensors, which is used under license. The securities based on the index are neither sponsored nor promoted, distributed or in any other manner supported by STOXX, Deutsche Börse Group or their licensors, research partners or data providers and STOXX, Deutsche Börse Group and their licensors, research partners or data providers do not give any warranty, and exclude any liability (whether in negligence or otherwise) with respect thereto generally or specifically in relation to any errors, omissions or interruptions in the EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) index or its data.*	
7.	Typology:	Max Long Certificates	
8.	(i) Exercise Date:	The Exercise Date of the Securities is 31 March 2032.	
	(ii) Renouncement Notice Cut-off Time:	Equal to the Valuation Date.	
9.	Settlement Date:	The Settlement Date for the Securities is 31 March 2032.	
		If, on the Valuation Date a Market Disruption Event occurs, the Settlement Date will be postponed accordingly. Such Settlement Date shall not, in any case, be postponed beyond the tenth Business Day following the Valuation Date.	
10.	Delivery Date:	The Delivery Date for the Securities is the Issue Date.	

11.	Issue Date:	The Issue Date is 31 March 2022, or, in case of postponement, such other date specified in a notice published on the website of the Issuer. The Issue Date shall not, in any case, be postponed beyond the fifth Business Day following 31 March 2022.
12.	Issue Currency:	The Issue Currency is Euro ("**EUR**").
13.	Discount Price	Not applicable.
14.	Purchase Price:	Not applicable.
15.	Business Day Centre(s):	The applicable Business Day Centre is Milan.
16.	Business Day:	Following Unadjusted Business Day Convention
17.	Exchange Business Day:	Following Unadjusted Business Day Convention
18.	Settlement Business Day:	Not applicable
19.	Settlement:	Settlement will be by way of cash payment (**Cash Settled Securities**).
20.	Exchange Rate:	Not applicable.
21.	Settlement Currency:	The Settlement Currency for the payment of the Cash Settlement Amount and any other remuneration amount payable under the Securities is EUR.
22.	Name and address of Calculation Agent:	The Calculation Agent is Intesa Sanpaolo S.p.A., with registered office at Piazza San Carlo, 156 10121 Turin.
23.	Exchange(s):	The relevant Exchange is, in respect of each component security of the Index (each an "**Index Constituent**"), the principal stock exchange on which such Index Constituent is principally traded, as determined by the Calculation Agent.
24.	Index Sponsor:	The Index Sponsor is STOXX Limited.
25.	Related Exchange(s):	The relevant Related Exchange is EUREX.
26.	Rollover Date:	Not applicable
27.	Open End Feature:	Not applicable
28.	Put Option:	Not applicable
29.	Call Option:	Not applicable
30.	Maximum Level:	Not applicable
31.	Minimum Level:	Not applicable

32.	Settlement Amount:	On the Settlement Date each Certificate will entitle its holder to receive a Cash Settlement Amount in the Settlement Currency calculated by the Calculation Agent in accordance with the following formula and rounding the resultant figure to nearest EUR cent, 0.005 EUR being rounded upwards: *{Min [Cap Level; Max [Initial Percentage x Initial Reference Value; (Initial Reference Value + Participation Factor x (Final Reference Value – Initial Reference Value))]] x Multiplier} x Minimum Exercise Amount*
33.	Multiplier:	The Multiplier to be applied is equal to the Issue Price divided by the Initial Reference Value.
34.	Relevant Asset(s):	Not applicable
35.	Entitlement:	Not applicable
36.	AMF Percentage:	Not applicable
37.	VMF Percentage:	Not applicable
38.	Strike Price:	Not applicable
39.	Conversion Rate:	Not applicable
40.	Underlying Reference Currency:	The Underlying Reference Currency is EUR.
41.	Quanto Option:	Not applicable
42.	Determination Date(s):	30 March 2022, 31 March 2022 and 1 April 2022
43.	Valuation Date(s):	25 March 2032
44.	Intraday Value:	Not applicable
45.	Reference Value:	For the purposes of the Participation Remuneration Amount, the Reference Value will be calculated on each Participation Valuation $Date_t$ and is equal to the closing level of the Underlying on such date.
46.	Initial Reference Value:	The Initial Reference Value will be calculated on 1 April 2022 and is equal to the arithmetic mean of the closing levels of the Underlying, determined by the Calculation Agent on the Determination Dates, and calculated pursuant to the following formula: $\boldsymbol{IRV} = \frac{1}{x} \times \sum_{t=1}^{x} Underlying_t$

		Where: "**IRV**" is the Initial Reference Value, "*x*" is the number of Determination Dates (*x* = 3), and "$Underlying_t$" is the closing level of the Underlying on the Determination Date "*t*" (*t = 1,2,3*).
	Initial Reference Value Determination Period(s):	Not applicable
47.	Final Reference Value:	The Final Reference Value will be calculated on the Valuation Date and is equal to the closing level of the Underlying on such date.
	Final Reference Value Determination Period(s):	Not applicable
48.	Best Of Feature:	Not applicable
49.	Worst Of Feature:	Not applicable
50.	Rainbow Feature:	Not applicable
51.	Reverse Split:	Not applicable

PROVISIONS RELATING TO CERTIFICATES

Applicable

52.	Performance Cap:	Not applicable
	Performance Floor:	Not applicable
	Performance Participation Factor:	Not applicable
53.	Initial Percentage:	100%
54.	Participation Factor:	100%
55.	Down Participation Factor:	Not applicable
56.	Up Participation Factor:	Not applicable
57.	Initial Leverage:	Not applicable
58.	Barrier Event:	Not applicable
	Barrier Event Determination Period(s):	Not applicable
	Barrier Level:	Not applicable
	Lower Barrier Level:	Not applicable

	Upper Barrier Level:	Not applicable
	Barrier Selection Period:	Not applicable
	Strike Observation Period:	Not applicable
	Air Bag Factor:	Not applicable
	Protection Level:	Not applicable
	Protection Percentage:	Not applicable
	Spread Protection:	Not applicable
	Protection Amount:	Not applicable
	Dropdown Protection Level:	Not applicable
	Dropdown Protection Amount:	Not applicable
	Dynamic Protection Level:	Not applicable
	Step Up Amount:	Not applicable
	Sigma Amount:	Not applicable
	Predetermined Loss Percentage:	Not applicable
	Short Protection:	Not applicable
	Butterfly Level:	Not applicable
59.	Barrier Gap Event:	Not applicable
60.	Cap Level(s):	Applicable. Equal to the product between the Cap Percentage and the Initial Reference Value.
	Cap Percentage:	100%
	Cap Amount:	Not applicable
	Cap Style 1:	Not applicable
	Cap Style 2:	Not applicable
61.	Consolidation Floor Event:	Not applicable
62.	Cap Barrier Amount:	Not applicable
63.	Cap Down Amount:	Not applicable
64.	Strike Percentage:	Not applicable
65.	Calendar Cap Percentage:	Not applicable
66.	Calendar Floor Percentage:	Not applicable
67.	Gearing Factor:	Not applicable

68.	One Star Event:	Not applicable
69.	Switch Event:	Not applicable
70.	Spread:	Not applicable
71.	Gearing Event:	Not applicable
72.	Buffer Event:	Not applicable
73.	Global Performance:	Not applicable
74.	Failure to Deliver due to Illiquidity:	Not applicable
75.	Digital Percentage:	Not applicable
76.	Settlement Level:	Not applicable
77.	Combined Amount:	Not applicable
78.	Darwin Feature:	Not applicable

PROVISIONS RELATING TO REMUNERATION AMOUNTS AND EARLY REDEMPTION AMOUNTS

79.	Knock-out Feature:	Not applicable
80.	Knock-in Feature:	Not applicable
81.	Digital Amount(s):	Not applicable
82.	Restrike Feature:	Not applicable
83.	Plus Amount(s):	Not applicable
84.	Accumulated Amount(s):	Not applicable
85.	Early Redemption Amount(s):	Not applicable
86.	Early Partial Capital Payment Amount:	Not applicable
87.	Coupon Event:	Not applicable
88.	Internal Return Amount:	Not applicable
89.	Participation Remuneration Amount:	Applicable. The Participation Remuneration Amounts are Long Participation Remuneration Amounts Form B, calculated according to the formula below: *Issue Price x Max {Floor Percentage; [Base Premium Percentage x (1 + Participation Remuneration Amount Gearing x (RV_t – RV_j) / RV_j)]}* Where: "**RV_t**" means the Reference Value on the Participation

	Valuation Date(s) "t" (t = 1,2,3,4,5,6,7,8,9,10) "**RV_j**" means the Initial Reference Value, as calculated on the Determination Dates (the "**Participation Valuation $Dates_j$**").
Participation Remuneration Payment Date(s):	31 March 2023 in relation to the First Participation Valuation Period 28 March 2024 in relation to the Second Participation Valuation Period 31 March 2025 in relation to the Third Participation Valuation Period 31 March 2026 in relation to the Fourth Participation Valuation Period 31 March 2027 in relation to the Fifth Participation Valuation Period 31 March 2028 in relation to the Sixth Participation Valuation Period 29 March 2029 in relation to the Seventh Participation Valuation Period 29 March 2030 in relation to the Eighth Participation Valuation Period 31 March 2031 in relation to the Ninth Participation Valuation Period 31 March 2032 in relation to the Tenth Participation Valuation Period.
Participation Valuation Period:	from the Participation Valuation $Dates_j$ to 27 March 2023 (the "**Participation Valuation $Date_1$**") (the "**First Participation Valuation Period**") from the Participation Valuation $Dates_j$ to 22 March 2024 (the "**Participation Valuation $Date_2$**") (the "**Second Participation Valuation Period**") from the Participation Valuation $Dates_j$ to 25 March 2025 (the "**Participation Valuation $Date_3$**") (the "**Third Participation Valuation Period**") from the Participation Valuation $Dates_j$ to 25 March 2026 (the "**Participation Valuation $Date_4$**") (the "**Fourth Participation Valuation Period**") from the Participation Valuation $Dates_j$ to 23 March 2027 (the "**Participation Valuation $Date_5$**") (the "**Fifth Participation Valuation Period**")

	from the Participation Valuation Dates$_j$ to 27 March 2028 (the "**Participation Valuation Date$_6$**") (the "**Sixth Participation Valuation Period**") from the Participation Valuation Dates$_j$ to 23 March 2029 (the "**Participation Valuation Dates$_7$**") (the "**Seventh Participation Valuation Period**") from the Participation Valuation Dates$_j$ to 25 March 2030 (the "**Participation Valuation Dates$_8$**") (the "**Eighth Participation Valuation Period**") from the Participation Valuation Dates$_j$ to 25 March 2031 (the "**Participation Valuation Dates$_9$**") (the "**Ninth Participation Valuation Period**") from the Participation Valuation Dates$_j$ to 25 March 2032 (the "**Participation Valuation Dates$_{10}$**") (the "**Tenth Participation Valuation Period**").
Strike Remuneration Percentage:	Not applicable
Floor Percentage:	0%
Cap:	Not applicable
Base Premium Percentage:	2.42%
Participation Remuneration Amount Gearing:	3
Net Profit Feature:	Not applicable
Tarn Feature:	Not applicable
Tarn Amount:	Not applicable
Participation Combo Feature:	Not applicable
Participation Factor$_t$:	Not applicable
Participation Remuneration Event:	Not applicable
Participation Remuneration Level(s):	Not applicable
Cliquet Feature:	Not applicable
Cliquet Valuation Period:	Not applicable
Participation Remuneration Event Valuation Period(s):	Not applicable

	Consolidation Effect:	Not applicable
	Consolidation Level:	Not applicable
	Consolidation Valuation Period(s):	Not applicable
	Memory Effect:	Not applicable
	Memory Level:	Not applicable
	Memory Valuation Period(s):	Not applicable
90.	Participation Rebate Feature:	Not applicable
91.	Floating Amount:	Not applicable
92.	Premium Gap Amount:	Not applicable

PROVISIONS RELATING TO WARRANTS

Not applicable.

93.	Type of Warrants:	Not applicable
94.	Notional Amount:	Not applicable
95.	Exercise Price:	Not applicable
96.	Premium:	Not applicable
97.	Barrier Event:	Not applicable
	Barrier Event Determination Period(s):	Not applicable
	Lower Barrier Level:	Not applicable
	Upper Barrier Level:	Not applicable
	Corridor Early Amount:	Not applicable
	Corridor Early Payment Date:	Not applicable
98.	Strike Percentage:	Not applicable
99.	Exercise Period:	Not applicable
100.	Maximum Exercise Number:	Not applicable
101.	Settlement Determination Period:	Not applicable
102.	Settlement Determination Date:	Not applicable

GENERAL

103.	Form of Securities:	Bearer Securities. Temporary Global Security exchangeable for a Permanent

		Global Security which is exchangeable for Definitive Securities only in the limited circumstances specified in the Permanent Global Security.
104.	Prohibition of Sales to Retail Investors:	Not applicable

DISTRIBUTION

105.	Syndication:	The Securities will be distributed on a non-syndicated basis.
	(i) If syndicated, names and addresses of Managers and underwriting commitments:	Not applicable.
	(ii) Date of Subscription Agreement:	Not applicable.
	(iii) Stabilising Manager (if any):	Not applicable
	If non-syndicated, name and address of Manager (if not the Issuer):	Not applicable.
	Total commission, concession and other costs:	The Offer Price embeds: – distribution commissions equal to 3.00 per cent. of the Issue Price in respect of the aggregate Securities distributed; – costs in relation to the maintenance of the conditions of the Offer equal to 1.80 per cent. of the Issue Price; and – other structuring costs equal to 0.30 per cent. of the Issue Price.

ADDITIONAL INFORMATION

Example(s) of complex derivatives securities:	Not applicable.

Signed on behalf of the Issuer:

By: .....

Duly authorised

PART B – OTHER INFORMATION

1. LISTING AND ADMISSION TO TRADING

(i)	Listing:	Application will be made in Luxembourg – Official List of the Luxembourg Stock Exchange
(ii)	Admission to trading:	Application will be made for the Securities to be admitted to trading on the regulated market of the Luxembourg Stock Exchange with effect from the Issue Date or a date around the Issue Date. Application will also be made for the Securities to be admitted to trading on the Italian multilateral trading facility Securitised Derivatives Market (the "**SeDeX**"), organised and managed by Borsa Italiana S.p.A., which is not a regulated market for the purposes of Directive 2014/65/EU as amended, with effect from the Issue Date or a date around the Issue Date. After the Issue Date application may be made to list the Securities on other stock exchanges or regulated markets or to admit to trading on other trading venues as the Issuer may decide.

2. NOTIFICATION

The CSSF has provided the Commissione Nazionale per le Società e la Borsa (CONSOB) with a certificate of approval attesting that the Base Prospectus has been drawn up in accordance with the Prospectus Regulation.

3. INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE

Intesa Sanpaolo S.p.A., the issuer of the Securities, will also act as Distributor, therefore it results in a conflict of interest.

The Issuer is expected to enter into hedging arrangements with market counterparties in connection with the issue of the Securities in order to hedge its exposure.

The Issuer will act as Calculation Agent under the Securities. See the risk factor "*Potential Conflicts of Interest*" of the Base Prospectus.

Save as discussed above and save for any commission and costs referred to in item 105 of Part A above, so far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the Offer.

4. REASONS FOR THE OFFER, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

(i)	Reasons for the offer:	See "Use of Proceeds" wording in Base Prospectus.
(ii)	Estimated net proceeds:	The net proceeds (resulting from subtracting the commissions and the costs referred to in item 105 of Part A, from the aggregate Issue Price paid by the Securityholders) of the issue

of the Securities will be up to EUR 142,350,000.

(iii) Estimated total expenses: Not applicable.

5. TERMS AND CONDITIONS OF THE OFFER

Applicable

Public Offer Jurisdiction(s):	Republic of Italy
Offer Price:	Issue Price. Investors should take into consideration that the Offer Price embeds distribution commissions and costs as described in Paragraph 105 of Part A above. Investors should also take into consideration that when the Securities are sold on the secondary market after the Offer Period, the above mentioned commissions and costs are not taken into consideration in determining the price at which such Securities may be sold on the secondary market.
Conditions to which the offer is subject:	Offer of the Securities is conditional on their issue and on the release by Borsa Italiana S.p.A., or by other trading venues, before the Issue Date, of the relevant authorisation to the admission to trading of the Securities.
The Offer Period, including any possible amendments, during which the offer will be open and description of the application process:	An offer (the "**Offer**") of the Securities will be made by the Distributor other than pursuant to Article 1(4) of the Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") in the Republic of Italy during the period from 23 February 2022 to and including 25 March 2022 or, in respect of sales by means of financial advisors authorised to make off-premises offers (*consulenti finanziari abilitati all'offerta fuori sede*) only, to and including 18 March 2022 or, in respect of sales by means of distance communication techniques only, to and including 11 March 2022 (the "**Offer Period**"). The Securities are being offered to the public in Italy pursuant to Articles 24 and 25 of the Prospectus Regulation. The Issuer reserves the right, in its sole discretion, to close the Offer Period early, also in circumstances where purchases of Securities are not yet equal to the maximum amount offered of 150,000 Securities. Notice of the early closure of the Offer Period will be given by the Issuer by publication on the website of the Issuer. The early closure of the Offer will become

effective from the date specified in such notice.

The Issuer reserves the right, in its sole discretion, to revoke or withdraw the Offer and the issue of the Securities at any time prior to the Issue Date. Notice of revocation/withdrawal of the Offer will be given by publication of such notice on the website of the Issuer. Revocation/withdrawal of the Offer will be effective upon publication. Upon revocation/withdrawal of the Offer, all subscription applications will become void and of no effect, without further notice.

The Issuer reserves the right to postpone the closure of the Offer Period, in order to extend the Offer Period. Notice of the postponement of the closure of the Offer Period will be given by the Issuer by publication on the website of the Issuer.

During the Offer Period, prospective investors may subscribe the Securities during normal Italian banking hours at the offices (*filiali*) of the Distributor by filling in, duly executing (also by appropriate attorneys) and delivering a specific acceptance form (the "**Acceptance Form**") (*Scheda di Adesione*).

The Acceptance Form is available at each Distributor's office.

Subscription of the Securities may also be made by means of financial advisors authorised to make off-premises offers (*consulenti finanziari abilitati all'offerta fuori sede*).

Subscription of the Securities may also be made by means of distance communication techniques.

There is no limit to the subscription application which may be filled in and delivered by the same prospective investor.

The subscription requests can be revoked by the potential investors through a specific request made at the office of the Distributor which has received the relevant subscription forms within 25 March 2022 also in case of early closure, or within the last day of the Offer Period as postponed in the event of an extension of the Offer.

Once the revocation terms are expired, the subscription of the Securities is irrevocable.

In addition to what stated above, in respect of subscription of the Securities made by means of

	financial advisors authorised to make off-premises offers (*consulenti finanziari abilitati all'offerta fuori sede*), subscription will be effective only after seven days following completion of the subscription form; by this deadline investor is fully entitled, at no cost and fees, to revoke its subscription by notice to the Distributor and/or the financial advisor authorised to make off-premises offers (*consulente finanziario abilitato all'offerta fuori sede*). Finally, in respect of subscription of the Securities made by means of distance communication techniques, subscription will be effective only after 14 days following completion of the subscription form; by this deadline investor classified as Consumer ("***Consumatore***") pursuant to article *67-duodecies* of Italian Legislative Decree 206/2005 ("***Codice del Consumo***"), is fully entitled, at no cost and fees, to revoke its subscription by notice to the Distributor. The Issuer may in certain circumstances, including but not limited to the filing of a supplement to the Base Prospectus, postpone the Issue Date. In the event that the Issuer gives notice that the Issue Date shall be postponed from 31 March 2022 to the other date specified in the relevant notice (which will fall within a period of five Business Days following 31 March 2022), investors will be entitled, at no cost and fees, to revoke their subscription within three Business Days before the postponed Issue Date.
Details of the minimum and/or maximum amount of the application:	The Securities may be subscribed in a minimum lot of no. 1 Security (the "**Minimum Exercise Amount**") and an integral number of Securities higher than the Minimum Exercise Amount and being an integral multiple of 1. There is no maximum amount of application within the maximum number of Securities offered of 150,000 Securities. The Issuer reserves the right to increase, during the Offer Period, the maximum amount of Securities offered. The Issuer shall forthwith give notice of any such increase by publication of a notice on the website of the Issuer.
Description of possibility to reduce subscriptions and manner for refunding amounts paid in excess by applicants:	Not applicable

Details of the method and time limits for paying up and delivering the Securities:	The total consideration for the Securities subscribed must be made by the investor on the Issue Date to the Distributor's office which has received the relevant Acceptance Form. The Securities will be delivered on the Issue Date, subsequent to the payment of the Offer Price, to potential Securityholders in the deposit accounts held, directly or indirectly, by the Distributor at Euroclear and/or Clearstream.
Manner in and date on which results of the offer are to be made public:	Not later than 5 days on which the TARGET2 System is open following the Issue Date (as postponed) the Issuer will notify the public of the results of the Offer through a notice published on the website of the Issuer.
Procedure for exercise of any right of pre-emption, negotiability of subscription rights and treatment of subscription rights not exercised:	Not applicable
Whether tranche(s) have been reserved for certain countries:	The Securities will be offered to the public only in Italy. Qualified investors, as defined in Article 2 (e) of the Prospectus Regulation, are allowed to subscribe any Securities.
Process for notifying to applicants of the amount allotted and an indication whether dealing may begin before notification is made:	The Distributor shall notify applicants with amounts allotted. Subscription applications will be satisfied until reaching the maximum number of Securities offered of 150,000 Securities and thereafter the Distributor will immediately suspend receipt of further subscription applications and the Offer Period will be closed early by the Issuer. Before the Issue Date, in the event that, notwithstanding the above, the aggregate amount of Securities requested to be subscribed exceed the maximum number of Securities offered of 150,000 Securities, the Issuer will allot the Securities in accordance with allotment criteria so to assure transparency and equal treatment amongst all potential subscribers thereof.
Amount of any expenses and taxes charged to the subscriber or purchaser:	No expenses and duties will be charged by the Issuer to the subscribers of the Securities. Investors should take into consideration that the Offer Price embeds distribution commissions and costs as

	described in Paragraph 105 of Part A.
Consent to use of Base Prospectus:	Not applicable.

6. DISTRIBUTION

(i)	Name(s) and address(es), to the extent known to the Issuer, of the Distributors in the various countries where the offer takes place:	The Issuer Intesa Sanpaolo S.p.A., with registered office at Piazza San Carlo, 156 – 10121 Torino, Italy will act as distributor of the Securities (the "**Distributor**").
(ii)	Name and address of the co-ordinator(s) of the global offer and of single parts of the offer:	The Issuer will also act as lead manager of the placement (*Responsabile del Collocamento*) as defined under article 93-*bis* of the Legislative Decree of 24 February 1998, n. 58, as subsequently amended (the "**Financial Services Act**").
(iii)	Name and address of any paying agents and depository agents in each country (in addition to the Principal Security Agent):	Not applicable.
(iv)	Entities agreeing to underwrite the issue on a firm commitment basis, and entities agreeing to place the issue without a firm commitment or under "best efforts" arrangements:	Not applicable.
(v)	Date of signing of the placement agreement:	Not applicable.

7. POST-ISSUANCE INFORMATION

The Issuer does not intend to provide post-issuance information, except if required by any applicable laws and regulations.

8. OPERATIONAL INFORMATION

(i)	ISIN Code:	XS2445136976
(ii)	Common Code:	244513697
(iii)	Any clearing system(s) other than Euroclear Bank S.A./N.V. and Clearstream Banking, S.A., relevant address(es), and relevant identification number(s):	Not applicable
(iv)	Names and addresses of initial Security Agents:	Société Générale Luxembourg 28-32 Place de la Gare, Luxembourg L-1616 Luxembourg

PART C – ISSUE SPECIFIC SUMMARY OF THE SECURITIES

Section 1 – Introduction containing warnings

Securities: MAX LONG CAP CERTIFICATES on EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) Index due 31.03.2032 (ISIN Code XS2445136976)

Issuer: Intesa Sanpaolo S.p.A. (**Intesa Sanpaolo**, the **Bank** or the **Issuer**)

Address: Piazza San Carlo 156, 10121 Turin, Italy

Phone number: +39 011555

Website: www.intesasanpaolo.prodottiequotazioni.com

Legal Entity Identifier (LEI): 2W8N8UU78PMDQKZENC08

Competent authority: *Commission de Surveillance du Secteur Financier* (**CSSF**), 283, route d'Arlon L-1150 Luxembourg. Phone number: (+352) 26 25 1 - 1.

Date of approval of the Base Prospectus: Warrants and Certificates Programme IMI Corporate & Investment Banking approved by the CSSF on 27 May 2021.

This Summary should be read as an introduction to the Base Prospectus.
Any decision to invest in the Securities should be based on consideration of the Base Prospectus as a whole by the investor.
Investors could lose all or part of the invested capital.
Where a claim relating to the information contained in the Base Prospectus is brought before a court, the plaintiff investor might, under the national legislation of the Member States, have to bear the costs of translating the Base Prospectus (including any supplements as well as the Final Terms) before the legal proceedings are initiated.

Civil liability attaches only to those persons who have tabled the Summary including any translation thereof, but only if the Summary is misleading, inaccurate or inconsistent when read together with the other parts of the Base Prospectus, or it does not provide, when read together with the other parts of the Base Prospectus, all necessary key information in order to aid investors when considering whether to invest in the Securities.

You are about to purchase a product that is not simple and may be difficult to understand.

Section 2 – Key information on the Issuer

Who is the issuer of the securities?

The Issuer is Intesa Sanpaolo S.p.A., registered with the Companies' Registry of Turin under registration number 00799960158 and with the National Register of Banks under no. 5361 and is the parent company of "Gruppo Intesa Sanpaolo". Intesa Sanpaolo S.p.A. operates subject to the Banking Law.

Domicile and legal form, its LEI, the law under which it operates and its country of incorporation

Intesa Sanpaolo's Legal Entity Identification number (LEI) is 2W8N8UU78PMDQKZENC08.

The Issuer is an Italian bank established as a company limited by shares (*società per azioni*).

The registered and administrative office of the Issuer is Piazza San Carlo 156, 10121 Turin, Italy.

The Issuer is incorporated and carries out its business under Italian law. The Issuer, both as a bank and as is the parent company of "Gruppo Intesa Sanpaolo", is subject to the Bank of Italy's and European Central Bank's prudential supervision.

Principal activities

The Issuer is a banking institution engaged in investment banking activities. The Issuer offers a wide range of capital markets, investment banking and special lending services to a diversified client base including banks, companies, institutional investors, entities and public bodies. The Issuer is the parent company of the "Gruppo Intesa Sanpaolo" which operates through six divisions: the Banca dei Territori division, the Corporate and Investment Banking division, the International Subsidiary Banks division, the Private Banking division, the Asset Management division and the Insurance Division.

Major shareholders, including whether it is directly or indirectly owned or controlled and by whom

As of 2 June 2021, the shareholder structure of the Issuer was composed as follows (holders of shares exceeding 3%): Compagnia di San Paolo (ordinary shares: 1,188,947,304; owned: 6.119%); BlackRock Inc. (ordinary shares: 972,416,733; owned: 5.005%); Fondazione Cariplo (ordinary shares: 767,029,267; owned: 3.948%). In addition, JP Morgan Chase & Co. holds an aggregate investment equal to 6.854% as per form 120 B dated 2 June 2021.

Identity of its key managing directors

The managing director of the Issuer is Carlo Messina (Chief Executive Officer).

Identity of its auditors

KPMG S.p.A., with registered office at Via V. Pisani, 25, 20121 Milan, was appointed by the Issuer as its independent auditor to audit its financial statements for the period 2012-2020.

What is the key financial information regarding the Issuer?[1]

Consolidated Income statement					
	As for the year ended			As for the half year ended	
EUR millions, except where indicated	31.12.21[2] *Unaudited*	31.12.20 *Audited*	31.12.19 *Audited*	30.06.21 *Unaudited*	30.06.20 *Unaudited*
Interest margin	not available	7,732	6,924	4,033	3,475
Net fee and commission income	not available	7,978	7,499	4,620	3,424
Profits (Losses) on trading	not available	628	506	409	305
Net losses/recoveries for credit risks	not available	(4,364)	(2,201)	(1,076)	(1,718)
Net income from banking and insurance activities	not available	14,148	15,742	9,532	7,195
Parent Company's net income (loss)	4,185	3,277	4,182	3,023	2,566

Consolidated Balance Sheet						
	As for the year ended			As for the half year /year ended		Value as outcome from the Supervisory Review and Evaluation Process ('SREP' requirement for 2021)[3]
EUR millions, except where indicated	31.12.21[1] *Unaudited*	31.12.20 *Audited*	31.12.19 *Audited*	30.06.21 *Unaudited*	31.12.20 *Audited*	
Total assets	1,069,003	1,002,614	816,102	1,057,595	1,002,614	not applicable
Senior debt (securities issued)	not available	80,048	75,569	75,627	80,048	not applicable

[1] Figures respectively from the unaudited consolidated results of Intesa Sanpaolo as at and for the year ended as at 31 December 2021, consolidated annual financial statements of Intesa Sanpaolo as at and for the year ended 31 December 2020, consolidated annual financial statements of Intesa Sanpaolo as at and for the year ended 31 December 2019 and from the consolidated financial statements of Intesa Sanpaolo as at and for the half year ended 30 June 2021.

[2] The financial information relating to 31 December 2021 has been extracted from the press release issued by Intesa Sanpaolo S.p.A. on 4 February 2022 and entitled "Intesa Sanpaolo: Consolidated Results as at 31 December 2021" (the "**2021 Results Press Release**"). The Issuer confirms that the unaudited results and other figures contained in the 2021 Results Press Release are consistent with the corresponding figures that will be contained in the Issuer's consolidated financial statements as at and for the year ended 31 December 2021 (the "**2021 Annual Report**").

[3] Applying the regulatory measure introduced by the ECB and effective from 12 March 2020.

Subordinated debt (securities issued)	not available	11,786	9,308	12,580	11,786	not applicable
Financial assets measured at amortised cost - Loans to customers	not available	505,165	418,788	501,976	505,165	not applicable
Financial liabilities measured at amortised cost - Due to customers	not available	422,365	331,181	not available	422,365	not applicable
Share capital	10,084	10,084	9,086	10,084	10,084	not applicable
Non performing loans	7,077	10,743	14,222	9,713	10,743	not applicable
Common Equity Tier 1 capital (CET1) ratio (%)	14.5%	14.7%	13.9%	14.9%	14.7%	8.64%[4]
Total Capital Ratio	19.1%	19.6%	17.7%	19.6%	19.6%	not available

What are the key risks that are specific to the Issuer?

Risk exposure to debt securities issued by sovereign States

The market tensions regarding government bonds and their volatility, as well as Italy's rating downgrading or the forecast that such downgrading may occur, might have negative effects on the assets, the economic and/or financial situation, the operational results and the perspectives of the Bank. Intesa Sanpaolo Group results is and will be exposed to sovereign debtors, in particular to Italy and certain major European Countries.

Risks related to legal proceedings

The risk arising from legal proceedings consists of the possibility of the Bank being obliged to pay any sum in case of unfavourable outcome.

Risks related to the economic/financial crisis and the impact of current uncertainties of the macro-economic context

The future development in the macro-economic context may be considered as a risk as it may produce negative effects and trends in the economic and financial situation of the Bank and/or the Group. Any negative variations of the factors that affect the macro-economic framework, in particular during periods of economic-financial crisis, could lead the Bank and/or the Group to suffer losses, increases of financing costs, and reductions of the value of the assets held, with a potential negative impact on the liquidity of the Bank and/or the Group and its financial soundness.

Credit risk

The economic and financial activity and soundness of the Bank depend on its borrower's creditworthiness. The Bank is exposed to the traditional risks related to credit activity. Therefore, the clients' breach of the agreements entered into and of their underlying obligations, or any lack of information or incorrect information provided by them as to their respective financial and credit position, could have negative effects on the economic and/or financial situation of the Bank.

Market risk

The market risk is the risk of losses in the value of financial instruments, including the securities of sovereign States held by the Bank, due to the movements of market variables (by way of example and without limitation, interest rates, prices of securities, exchange rates), which could determine a deterioration of the financial soundness of the Bank and/or the Group. Such deterioration could be produced either by negative effects on the income statement deriving from positions held for trading purposes, or from negative changes in the FVOCI (Fair Value through Other Comprehensive Income) reserve, generated by positions classified as financial Activities evaluated at fair value, with an impact on the overall profitability.

Liquidity risk

[4] 8.81% from 1st March 2022 (please refer to the press release issued by Intesa Sanpaolo S.p.A. on 3 February 2022 and entitled "Intesa Sanpaolo comfortably meets the Capital Requirements set by the ECB").

The liquidity risk is the risk that the Bank is not able to satisfy its payment obligations at maturity, both due to the inability to raise funds on the market (funding liquidity risk) and of the difficulty to disinvest its own assets (market liquidity risk).

Operational risk

The Bank is exposed to several categories of operational risk which are intrinsic to its business, among which those mentioned herein, by way of example and without limitation: frauds by external persons, frauds or losses arising from the unfaithfulness of the employees and/or breach of control procedures, operational errors, defects or malfunctions of computer or telecommunication systems, computer virus attacks, default of suppliers with respect to their contractual obligations, terrorist attacks and natural disasters. The occurrence of one or more of said risks may have significant negative effects on the business, the operational results and the economic and financial situation of the Bank.

Regulatory framework

The Bank is subject to a complex and strict regulation, as well as to the supervisory activity performed by the relevant institutions (in particular, the European Central Bank, the Bank of Italy and CONSOB). Both the aforementioned regulation and supervisory activity are subject, respectively, to continuous updates and practice developments. Furthermore, as a listed Bank, the Bank is required to comply with further provisions issued by CONSOB. The Bank, besides the supranational and national rules and the primary or regulatory rules of the financial and banking sector, is also subject to specific Rules on anti-money laundering, usury and consumer protection. Although the Bank undertakes to comply with the set of rules and regulations, any changes of the rules and/or changes of the interpretation and/or implementation of the same by the competent authorities could give rise to new burdens and obligations for the Bank, with possible negative impacts on the operational results and the economic and financial situation of the Bank.

Section 3 – Key information on the Securities

Type, class and ISIN

The Securities are Certificates. The Securities are issued in bearer form ("**Bearer Securities**").

The Certificates are cash settled.

The ISIN of the Certificates is XS2445136976

Currency, denomination, and term of the securities

The issue price of the Certificates is equal to EUR 1,000 (the "**Issue Price**").

The Securities are issued in EUR (the "**Issue Currency**").

The Settlement Currency is EUR.

Each Certificate shall be automatically exercised on the Exercise Date. The Exercise Date and Settlement Date is 31 March 2032.

Rights attached to the securities

The Certificates and any non-contractual obligations arising out of or in connection with the Certificates will be governed by, and shall be construed in accordance with, English Law.

The Certificates entitle its holder to receive from the Issuer the following amounts.

REMUNERATION AMOUNT

The Certificates provide for the following remuneration amount.

PARTICIPATION REMUNERATION AMOUNTS

The Certificates provide for the Participation Remuneration Amounts.

The Participation Remuneration Amounts are Long Participation Remuneration Amounts Form B, linked to the long performance of the Underlying (the "**Participation Remuneration Amounts**"). Such performance will be determined from the Determination Dates (the "**Participation Valuation Dates$_j$**") to

27 March 2023 (the "**Participation Valuation Date$_1$**") (the "**First Participation Valuation Period**");

22 March 2024 (the "**Participation Valuation Date$_2$**") (the "**Second Participation Valuation Period**");

25 March 2025 (the "**Participation Valuation Date$_3$**") (the "**Third Participation Valuation Period**");

25 March 2026 (the "**Participation Valuation Date$_4$**") (the "**Fourth Participation Valuation Period**");

23 March 2027 (the "**Participation Valuation Date$_5$**") (the "**Fifth Participation Valuation Period**");

27 March 2028 (the "**Participation Valuation Date$_6$**") (the "**Sixth Participation Valuation Period**");

23 March 2029 (the "**Participation Valuation Dates$_7$**") (the "**Seventh Participation Valuation Period**");

25 March 2030 (the "**Participation Valuation Dates$_8$**") (the "**Eighth Participation Valuation Period**");

25 March 2031 (the "**Participation Valuation Dates$_9$**") (the "**Ninth Participation Valuation Period**");

25 March 2032 (the "**Participation Valuation Dates$_{10}$**") (the "**Tenth Participation Valuation Period**").

****

CASH SETTLEMENT AMOUNT

The Securityholder will receive on the Settlement Date, for each Minimum Exercise Amount, the payment of the Cash Settlement Amount determined as follows.

MAX LONG CAP CERTIFICATES

CALCULATION METHOD IN THE CASE OF POSITIVE AND NEGATIVE PERFORMANCE OF THE UNDERLYING

The investor will receive a percentage of the Issue Price equal to 100% with the possibility to receive a higher amount participating to the long performance of the Underlying depending on a percentage equal to 100% (the "**Participation Factor**"). The Cash Settlement Amount will not exceed the Cap Level, equal to 100% of the Initial Reference Value multiplied by the Multiplier.

****

For the purposes of the above the following applies:

For the purposes of the Participation Remuneration Amount, the Reference Value will be calculated on each Participation Valuation Date$_t$ and is equal to the closing level of the Underlying on such date.

The Initial Reference Value will be calculated on 1 April 2022 and is equal to the arithmetic mean of the closing levels of the Underlying determined by the Calculation Agent on 30 March 2022, 31 March 2022 and 1 April 2022 (the "**Determination Dates**").

The Final Reference Value will be calculated on 25 March 2032 (the "**Valuation Date**") and is equal to the closing level of the Underlying on such date.

The Underlying is the EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) Index (ISIN Code: CH1123123734; Bloomberg Code: ISX5HCTD <Index>).

The EURO iSTOXX® 50 Future Healthcare Tilted NR Decrement 5% (EUR - PRICE) Index is provided by STOXX Limited. As at the date of these Final Terms, STOXX Limited appears in the register of administrators and benchmarks established and maintained by ESMA pursuant to Article 36 of the Benchmark Regulation.

In respect of the Underlying, certain historical information (including past performance thereof) may be found on major information providers, such as Bloomberg and Reuters. Information about the Index may be found on the website of the Index Sponsor www.stoxx.com

Seniority of the securities

The Certificates constitute direct, unsubordinated, unconditional and unsecured obligations of the Issuer and, unless provided otherwise by law, rank *pari passu* among themselves and (save for certain obligations required to be preferred by law) rank equally with all other unsecured obligations (other than subordinated obligations, if any) of the Issuer from time to time outstanding.

Restrictions on the free transferability

The Securities will be freely transferable, subject to the offering and selling restrictions in the United States, the European Economic Area under the Prospectus Regulation and the laws of any jurisdiction in which the relevant Securities are offered or sold.

Where will the securities be traded?

Application will be made by the Issuer (or on its behalf) for the Securities to be admitted to trading on the regulated market of the Luxembourg Stock Exchange with effect from the Issue Date or a date around the Issue Date.

Application will also be made by the Issuer (or on its behalf) for the Securities to be admitted to trading on the Italian multilateral trading facility Securitised Derivatives Market (the "**SeDeX**"), organised and managed by Borsa Italiana S.p.A., which is not a regulated market for the purposes of Directive 2014/65/EU as amended, with effect from the Issue Date or a date around the Issue Date.

After the Issue Date, application may be made to list the Securities on other stock exchanges or regulated markets or to admit to trading on other trading venues as the Issuer may decide.

What are the key risks that are specific to the securities?

The Certificates may not be a suitable investment for all investors

Certificates are complex financial instruments. A potential investor should not invest in Certificates which are complex financial instruments unless it has the expertise (either alone or with the help of a financial adviser) to evaluate how the Certificates will perform under changing conditions, the resulting effects on the value of the Certificates and the impact this investment will have on the potential investor's overall investment portfolio.

General risks and risks relating to the Underlying

The Securities involve a high degree of risk, which may include, among others, interest rate, foreign exchange, time value and political risks. Purchasers should be prepared to sustain a partial loss of the purchase price of their Securities. Fluctuations in the value of the relevant Underlying will affect the value of the Securities.

Risk arising from the Benchmark Regulation

The Underlying may qualify as a benchmark (the "**Benchmark**") within the meaning of Regulation (EU) 2016/1011 of the European Parliament and of the Council dated 8 June 2016 on indices used as benchmarks in financial instruments and financial contracts or to measure the performance of investment funds and amending Directives 2008/48/EC and 2014/17/EU and Regulation (EU) No 596/2014 (the "**Benchmark Regulation**"). Any changes to a Benchmark as a result of the Benchmark Regulation could have a material adverse effect on the costs of refinancing a Benchmark or the costs and risks of administering or otherwise participating in the setting of a Benchmark and complying with the Benchmark Regulation. Such factors may have the following effects on certain Benchmarks: (i) discourage market participants from continuing to administer or contribute to such Benchmark; (ii) trigger changes in the rules or methodologies used in the Benchmarks; or (iii) lead to the disappearance of the Benchmark. Any of the above changes or any other consequential changes as a result of international, national or other proposal for reform or other initiatives or investigations, could have a material adverse effect on the value of and the amount payable under the Securities. The potential elimination of a Benchmark, or changes in the manner of administration of such Benchmark, as a result of the Benchmark Regulation or otherwise, could require an adjustment to the terms and conditions, or result in other consequences. These reforms and changes may cause a Benchmark to perform differently than it has done in the past or be discontinued. The application of the fallback methods may expose investors to certain risks including, but not limited to (i) conflicts of interest of the Calculation Agent when making the required adjustments to the Securities, or (ii) the replacement of the Underlying with a different Underlying which could perform differently than the original Underlying and therefore affect amounts payable in respect of the Securities, or (iii) the early redemption of the Securities. Investors should be aware that they face the risk that any changes to the relevant Benchmark may have a material adverse effect on the value of and the amount payable under the Securities.

Certain considerations associated with Securities providing for the application of a cap

The Securities provide for the application of a maximum return payable to investors. Therefore, the amounts payable to investors will be subject to such predetermined maximum.

Impact of implicit fees on the Issue Price/Offer Price

Investors should note that implicit fees (e.g. placement commissions/distribution commissions, structuring fees) may be a component of the Issue Price/Offer Price of the Securities, but such fees will not be taken into account for the purposes of determining the price of the relevant Securities in the secondary market. Investors should also take into consideration that if Securities are sold on the secondary market immediately following the offer period relating to such Securities, the implicit fees included in the Issue Price/Offer Price on initial subscription for such Securities will be deducted from the price at which such Securities may be sold in the secondary market.

Possible illiquidity of the Securities in the secondary market

It is not possible to predict the price at which Securities will trade in the secondary market or whether such market will be liquid or illiquid. The Issuer, or any of its Affiliates may, but is not obliged to, at any time purchase Securities at any price in the open market or by tender or private treaty. Any Securities so purchased may be held or resold or surrendered for cancellation. The Issuer or any of its Affiliates may, but is not obliged to, be a market-maker for an issue of Securities. Even if the Issuer or such other entity is a market-maker for an issue of Securities, the secondary market for such Securities may be limited. To the extent that an issue of Securities becomes illiquid, an investor may have to wait until the Exercise Date to realise value.

Section 4 – Key information on the offer of securities to the public

Under which conditions and timetable can I invest in this security?

General terms, conditions and expected timetable of the offer

Public Offer Jurisdiction(s): Republic of Italy

Maximum number of Securities offered: 150,000

Offer Price: EUR 1,000.

Offer Period: from 23 February 2022 to and including 25 March 2022 or, in respect of sales by means of financial advisors authorised to make off-premises offers (*consulenti finanziari abilitati all'offerta fuori sede*) only, to and including 18 March 2022 or, in respect of sales by means of distance communication techniques only, to and including 11 March 2022 (the "**Offer Period**").

Conditions to which the offer is subject: The offer of the Securities is conditional on their issue and on the release by Borsa Italiana S.p.A., or by other trading venues, before the Issue Date, of the relevant authorisation to the admission to trading of the Securities.

Terms of the Offer: This issue of Securities is being offered in a Non-Exempt Offer in Italy pursuant to Articles 24 and 25 of the Prospectus Regulation. The Securities will be distributed by way of public offer and the distribution activities will be carried out by

the Distributor.

The Issuer reserves the right, in its sole discretion, to close the Offer Period early, also in circumstances where purchases of Securities are not yet equal to the maximum amount offered of 150,000 Securities. Notice of the early closure of the Offer Period will be given by the Issuer by publication on the website of the Issuer. The early closure of the Offer will become effective from the date specified in such notice. The Issuer reserves the right to postpone the closure of the Offer Period, in order to extend the Offer Period. Notice of the postponement of the closure of the Offer Period will be given by the Issuer by publication on the website of the Issuer. The Issuer reserves the right to increase, during the Offer Period, the maximum amount of Securities offered. The Issuer shall forthwith give notice of any such increase by publication of a notice on the website of the Issuer. The Issuer reserves the right, in its sole discretion, to revoke or withdraw the Offer and the issue of the Securities at any time prior to the Issue Date. Notice of revocation/withdrawal of the Offer will be given by publication of such notice on the website of the Issuer. Revocation/withdrawal of the Offer will be effective upon publication. Upon revocation/withdrawal of the Offer, all subscription applications will become void and of no effect, without further notice.

Minimum and maximum subscription amount: The Securities may be subscribed in a minimum lot of no. 1 Security (the "**Minimum Exercise Amount**") and an integral number of Securities higher than the Minimum Exercise Amount and being an integral multiple of 1. There is no maximum amount of application within the maximum number of Securities offered of 150,000 Securities.

Expenses charged to the investor by the issuer or the offeror

The Offer Price embeds:

- distribution commissions equal to 3.00 per cent. of the Issue Price in respect of the aggregate Securities distributed;
- costs in relation to the maintenance of the conditions of the Offer equal to 1.80 per cent. of the Issue Price; and
- other structuring costs equal to 0.30 per cent. of the Issue Price.

Who is the offeror?

The Issuer Intesa Sanpaolo S.p.A., with registered office at Piazza San Carlo, 156 – 10121 Turin, Italy, will act as Distributor of the Securities (the "**Distributor**").

The Issuer will also act as lead manager of the placement (*Responsabile del Collocamento*) as defined under article 93-bis of the Legislative Decree of 24 February 1998, n. 58, as subsequently amended.

Reasons for the offer and estimated net amount of the proceeds

The Issuer intends to use the net proceeds from each issue of Certificates for general corporate purposes, including making a profit. A substantial portion of the proceeds may be used to hedge market risks with respect to the Certificates.

The net proceeds (resulting from subtracting the commissions and the costs referred to above from the aggregate Issue Price paid by the Securityholders) of the issue of the Securities will be up to EUR 142,350,000.

Indication of whether the offer is subject to an underwriting agreement on a firm commitment basis

Not applicable.

Indication of the most material conflicts of interest pertaining to the offer or the admission to trading.

Intesa Sanpaolo S.p.A., the issuer of the Securities, will also act as Distributor, therefore it results in a conflict of interest.

The Issuer is expected to enter into hedging arrangements with market counterparties in connection with the issue of the Securities in order to hedge its exposure.

The Issuer will act as Calculation Agent under the Securities.

Save as discussed above and save for any commission and costs referred to above, so far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the Offer.